How soon will I lose weight on Wegovy — and what should you realistically expect?

The first few weeks: your body adjusting, not transforming

Picture this: it's a Tuesday evening, your first Wegovy pen is in the fridge, and you're wondering whether the number on the scales will move by next weekend. The honest answer is: possibly, but not dramatically. The starting dose (0.25mg) exists to let your digestive system settle, not to drive significant weight loss. Nausea, mild indigestion or a reduced appetite are common in these early weeks, and they can actually feel encouraging once you know what they signal.

Most people report a modest reduction in the first month, often in the range of one to two kilograms, largely from reduced calorie intake as appetite drops. That might feel underwhelming after the coverage Wegovy has had. It's worth knowing that every large trial, including the STEP 1 study published in the New England Journal of Medicine, built its headline results over more than a year, not a fortnight. The early weeks are foundation-laying. Progress is real; it just isn't always visible yet.

If you're impatient with the pace, you're not alone. A question our prescribers hear regularly is whether the starting dose is doing anything at all. It is, your system is adapting to a medicine that will eventually slow gastric emptying and reduce appetite substantially. That takes time to calibrate safely.

Months two to six: where most of the change happens

Once the dose escalates (from 0.5mg to 1.0mg and then to 1.7mg, each step roughly four weeks apart) weight loss typically accelerates. This is the window where people often notice clothes fitting differently, energy shifting, and the scales moving more consistently.

The STEP 1 trial recorded an average weight reduction of around 15% at the 2.4mg maintenance dose over 68 weeks, compared with roughly 2.4% in the placebo group. The majority of that loss occurred during the dose-escalation phase and the early months on the maintenance dose. By the six-month mark, many participants had achieved a significant proportion of their eventual total loss.

Diet and activity matter here more than at any other point. Wegovy reduces hunger, but it works alongside a reduced-calorie diet and regular movement, not instead of them. For practical guidance on getting the most from this phase, our page on maximising results on Wegovy covers protein intake, hydration and the role of activity in concrete terms. None of it is complicated, but the combination is what the trial data actually measured.

If you are also thinking about the relative cost of staying on treatment over several months, a straightforward comparison of Wegovy pricing in the UK may help you plan ahead.

Months six to eighteen: the maintenance stretch, and why it matters

Reaching the 2.4mg maintenance dose is not the finish line; it is where the real work of consolidating loss begins. Clinical trial data consistently shows that people who discontinue GLP-1 medicines regain a substantial portion of lost weight, which is why NICE recommends semaglutide for a maximum of two years within an appropriate clinical framework, and why every repeat prescription at nume is reviewed individually rather than issued automatically.

The NHS medicines information for semaglutide explains that this medicine works best as part of a longer-term plan, not a short course. Progress in months six to eighteen is slower in terms of absolute weight, but the biology of weight maintenance is genuinely different from the biology of weight loss, and keeping the lost weight off is its own medical achievement.

A small number of people find that weight loss stalls before the six-month mark at the highest tolerated dose. NICE guidance notes that if less than 5% weight loss is achieved after six months on the maintenance dose, continuing treatment should be reviewed. That review is exactly what a clinician is for, not a reason to feel the medicine has failed you personally. Bodies differ. Prescribers account for that. For a broader look at whether Wegovy will work for you specifically, including the factors that predict a stronger or more modest response, that page goes into more detail.

Wegovy's newer 7.2mg dose (approved by the MHRA in April 2026) is showing average reductions approaching those seen with tirzepatide in early data, which may extend the options available to people whose results plateau at 2.4mg. Specific availability of any dose format is confirmed at the time of your consultation rather than assumed in advance. If you want to understand how Wegovy is characterised and prescribed across different clinical settings, the Wegovy Vidal reference gives a useful overview of its classification and approved use. You can read more about Wegovy's full clinical profile or explore the semaglutide science in depth if you want the mechanism laid out clearly before you decide anything.

Ready to talk through whether Wegovy is appropriate for your situation? Speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, not a chatbot.